Cargando…

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension

Background: Hypoparathyroidism (HP) is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubin, Mishaela R, Rejnmark, Lars, Schwarz, Peter E, Vokes, Tamara J, Clarke, Bart, Ahmed, Intekhab, Hofbauer, Lorenz C, Palermo, Andrea, Marcocci, Claudio, Pagotto, Uberto, Eriksen, Erik F, Mourya, Sanchita, Markova, Denka, Pihl, Susanne, Shu, Aimee D, Khan, Aliya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090331/ http://dx.doi.org/10.1210/jendso/bvab048.514

Ejemplares similares

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

Disease Burden of Patients Living With Hypoparathyroidism: Results From the Voices of Hypopara Survey
por: Murphy, Deborah, et al.
Publicado: (2021)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism
por: Clarke, Bart L, et al.
Publicado: (2020)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

SAT-408 Bioactivity of Long Acting PTH Fusion Molecules Tested in a Novel Non-Surgical Animal Model of Hypoparathyroidism
por: Wilkinson, Ian R, et al.
Publicado: (2020)

ODP118 PTH (1-34) Replacement Therapy for Hypoparathyroidism due to Sporadic Calcium Sensing Receptor Gain-of-Function Point Mutation
por: Basina, Marina, et al.
Publicado: (2022)

MON-523 Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

SAT237 AZP-3601, A Novel PTH 1 Receptor Agonist, Induces Rapid Reduction And Normalization Of Urinary Calcium In Chronic Hypoparathyroid Patients
por: Figueres, Lucile, et al.
Publicado: (2023)

OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial
por: Kamenicky, Peter, et al.
Publicado: (2023)

MON-LB091 An Overview of the Etiology, Clinical Manifestations, Management Strategies, and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry
por: Alalawi, Yousef, et al.
Publicado: (2019)

MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism
por: Saponaro, Federica, et al.
Publicado: (2020)

MON-524 Risk of Decline in Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Delayed Diagnosis of Congenital Hypoparathyroidism in a Kindred of Three Patients With Autosomal Dominant Deafness
por: Dandurand, Karel, et al.
Publicado: (2021)

PSAT201 Hypoparathyroidism (HypoPT) in 16 Pregnancies in 7 Patients: A Case Series of Maternal and Neonatal Outcomes
por: Ali, Dalal S, et al.
Publicado: (2022)

OR07-01 Identification of the First Case of Acquired Autoimmune Parathyroid Hormone (PTH) Resistance Due to PTH1 Receptor (PTH1R) Autoantibodies
por: Mandl, Adel, et al.
Publicado: (2020)

MON-530 Hypoparathyroidism in Sweden
por: Kamal, Wafa, et al.
Publicado: (2019)

SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study
por: Mazoni, Laura, et al.
Publicado: (2020)

MON-533 Irisin in Post-Menopausal Women with Primary Hyperparathyroidism: An Interplay between Irisin and Pth
por: Palermo, Andrea, et al.
Publicado: (2019)

MON-527 Cardiovascular Autonomic Neuropathy As A Cause Of Quality Of Life Impairment In Subjects With Chronic Hypoparathyroidism.
por: Tabacco, Gaia, et al.
Publicado: (2019)

PSAT216 Turner Syndrome and Congenital Hypoparathyroidism
por: Jovanovic, Filip, et al.
Publicado: (2022)

FRI698 Hypoparathyroidism Secondary To Covid-19
por: Hussain, Mariam, et al.
Publicado: (2023)

Improving the Accuracy and Reliability of Parathyroid Hormone Levels Through the Mass-Spectrometric Measurement of Full-length PTH and C-Terminal PTH Fragments
por: Ulmer, Candice Z, et al.
Publicado: (2021)

OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
por: Bilezikian, John, et al.
Publicado: (2019)

PSAT209 A Remission of Hypocalcemia in Idiopathic Hypoparathyroidism
por: Puzio, Helene, et al.
Publicado: (2022)

SAT234 Variations In Clinical Practice Patterns For Hypoparathyroidism
por: Deering, Kathleen L, et al.
Publicado: (2023)

MON-538 Ca(2+)Allostery in PTH-Receptor Signaling
por: White, Alex, et al.
Publicado: (2019)

Ectopic Intact PTH Secretion Causing Humoral Hypercalcemia of Malignancy
por: Rauf, Mohammad Talha, et al.
Publicado: (2021)

PTH Protects Osteocytes From Oxidative Stress and Cellular Senescence
por: Uda, Yuhei, et al.
Publicado: (2021)

SUN-519 Hypoparathyroidism after Harvoni Treatment for Hepatitis C
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SUN-516 Fahr's Syndrome: A Rare Sequela of Hypoparathyroidism
por: Min, Lei Lei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ps0v185676os6a0simgq0ghrul